These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

837 related items for PubMed ID: 20104935

  • 1. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B.
    Circulation; 2005 Mar 08; 111(9):1106-13. PubMed ID: 15723981
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G, Solesse A, Beillat M.
    Arch Cardiovasc Dis; 2008 Sep 08; 101(9):515-21. PubMed ID: 19041835
    [Abstract] [Full Text] [Related]

  • 4. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.
    Health Technol Assess; 2010 May 08; 14(24):1-162. PubMed ID: 20492762
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
    Szucs TD, Holm MV, Schwenkglenks M, Zhang Z, Weintraub WS, Burnier M, Erne P.
    Cardiovasc Drugs Ther; 2006 Jun 08; 20(3):193-204. PubMed ID: 16775667
    [Abstract] [Full Text] [Related]

  • 6. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
    Croom KF, Plosker GL.
    Pharmacoeconomics; 2005 Jun 08; 23(10):1057-72. PubMed ID: 16235978
    [Abstract] [Full Text] [Related]

  • 7. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M, Khan S, Blair JE, Harinstein ME, Krum H, Mukherjee R, Pitt B, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival (EPHESUS) Investigators.
    Am Heart J; 2009 Sep 08; 158(3):437-43. PubMed ID: 19699868
    [Abstract] [Full Text] [Related]

  • 8. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
    Am Heart J; 2004 Jul 08; 148(1):122-8. PubMed ID: 15215801
    [Abstract] [Full Text] [Related]

  • 9. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
    Banka G, Heidenreich PA, Fonarow GC.
    J Am Coll Cardiol; 2013 Apr 02; 61(13):1440-6. PubMed ID: 23433562
    [Abstract] [Full Text] [Related]

  • 10. Cost effectiveness of eplerenone in patients with chronic heart failure.
    Ademi Z, Pasupathi K, Krum H, Liew D.
    Am J Cardiovasc Drugs; 2014 Jun 02; 14(3):209-16. PubMed ID: 24610254
    [Abstract] [Full Text] [Related]

  • 11. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S, Zhang Y, Fay R, Angioi M, Vincent J, Sutradhor SC, Ahmed A, Pitt B, Zannad F.
    Arch Cardiovasc Dis; 2014 Mar 02; 107(3):149-57. PubMed ID: 24630753
    [Abstract] [Full Text] [Related]

  • 12. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
    Krum H, Shi H, Pitt B, McMurray J, Swedberg K, van Veldhuisen DJ, Vincent J, Pocock S, Zannad F, EMPHASIS-HF Study Group.
    Circ Heart Fail; 2013 Jul 02; 6(4):711-8. PubMed ID: 23625945
    [Abstract] [Full Text] [Related]

  • 13. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr 02; 15(82):46-9. PubMed ID: 16604728
    [Abstract] [Full Text] [Related]

  • 14. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators.
    Circulation; 2008 Oct 14; 118(16):1643-50. PubMed ID: 18824643
    [Abstract] [Full Text] [Related]

  • 15. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
    Chan PS, Soto G, Jones PG, Nallamothu BK, Zhang Z, Weintraub WS, Spertus JA.
    Circulation; 2009 Jan 27; 119(3):398-407. PubMed ID: 19139382
    [Abstract] [Full Text] [Related]

  • 16. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH, Abuissa H, Pitt B.
    Diabetes Obes Metab; 2008 Jun 27; 10(6):492-7. PubMed ID: 17490427
    [Abstract] [Full Text] [Related]

  • 17. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
    Bauersachs J, Ertl G.
    Med Klin (Munich); 2006 Jun 15; 101(6):458-66. PubMed ID: 16767569
    [Abstract] [Full Text] [Related]

  • 18. Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study).
    Spertus JA, Tooley J, Jones P, Poston C, Mahoney E, Deedwania P, Hurley S, Pitt B, Weintraub WS.
    Am Heart J; 2002 Apr 15; 143(4):636-42. PubMed ID: 11923800
    [Abstract] [Full Text] [Related]

  • 19. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ, Howard PA.
    Ann Pharmacother; 2005 Jan 15; 39(1):68-76. PubMed ID: 15590870
    [Abstract] [Full Text] [Related]

  • 20. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
    MMW Fortschr Med; 2004 Oct 21; 146(43):58-9. PubMed ID: 15559524
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.